Cargando…
Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cel...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096791/ https://www.ncbi.nlm.nih.gov/pubmed/33682324 http://dx.doi.org/10.1002/1878-0261.12938 |
_version_ | 1783688217350897664 |
---|---|
author | Parveen, Sadiya Siddharth, Sumit Cheung, Laurene S. Kumar, Alok Shen, Jessica Murphy, John R. Sharma, Dipali Bishai, William R. |
author_facet | Parveen, Sadiya Siddharth, Sumit Cheung, Laurene S. Kumar, Alok Shen, Jessica Murphy, John R. Sharma, Dipali Bishai, William R. |
author_sort | Parveen, Sadiya |
collection | PubMed |
description | In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R(+) cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ(+) CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study. |
format | Online Article Text |
id | pubmed-8096791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80967912021-05-10 Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model Parveen, Sadiya Siddharth, Sumit Cheung, Laurene S. Kumar, Alok Shen, Jessica Murphy, John R. Sharma, Dipali Bishai, William R. Mol Oncol Research Articles In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R(+) cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ(+) CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study. John Wiley and Sons Inc. 2021-03-24 2021-05 /pmc/articles/PMC8096791/ /pubmed/33682324 http://dx.doi.org/10.1002/1878-0261.12938 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Parveen, Sadiya Siddharth, Sumit Cheung, Laurene S. Kumar, Alok Shen, Jessica Murphy, John R. Sharma, Dipali Bishai, William R. Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title_full | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title_fullStr | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title_full_unstemmed | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title_short | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
title_sort | therapeutic targeting with dabil‐4 depletes myeloid suppressor cells in 4t1 triple‐negative breast cancer model |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096791/ https://www.ncbi.nlm.nih.gov/pubmed/33682324 http://dx.doi.org/10.1002/1878-0261.12938 |
work_keys_str_mv | AT parveensadiya therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT siddharthsumit therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT cheunglaurenes therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT kumaralok therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT shenjessica therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT murphyjohnr therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT sharmadipali therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT bishaiwilliamr therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel |